Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UMPS | P11172 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | STAT6 | P42226 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | PYGL | P06737 | 6/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL164884 | 1.00 | UMPS (0.48) | UMPSKDM4EMAPTBLMSMN1; SMN2 | |
| SCHEMBL7893929 | 0.86 | UMPS (0.54) | UMPSKDM4EMAPTBLMSMN1; SMN2 | |
| SCHEMBL3810818 | 0.85 | KDM4E (0.44) | UMPSKDM4EMAPTBLMSMN1; SMN2 | |
| SCHEMBL30669424 | 0.83 | KDM4E (0.42) | UMPSKDM4EMAPTBLMSMN1; SMN2 | |
| SCHEMBL1980709 | 0.82 | UMPS (0.44) | UMPSKDM4EMAPTBLMSMN1; SMN2 | |
| SCHEMBL27596793 | 0.82 | UMPS (0.44) | UMPSKDM4EMAPTBLMSMN1; SMN2 | |
| SCHEMBL5547964 | 0.82 | UMPS (0.54) | UMPS | |
| SCHEMBL218016 | 0.81 | UMPS (0.54) | UMPSKDM4EMAPTBLMSMN1; SMN2 | |
| SCHEMBL8493435 | 0.80 | ADORA2A (0.34) | UMPSKDM4EMAPTBLMSMN1; SMN2 | |
| SCHEMBL8498082 | 0.80 | ADORA2A (0.36) | UMPSKDM4EMAPTBLMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180289731-A1 | Patient Treatment Via Teratogenic Pharmaceutical Compounds | NANT HOLDINGS IP, LLC | 2018-10-11 | — | — | US | claimed |
| US-20140186306-A1 | NOVEL AMPK AGONIST COMPOSITIONS AND METHODS OF USE | PLANTE PAUL RONALD (US) | 2014-07-03 | — | — | US | disclosed |
| EP-1370539-A1 | HIV INHIBITING N-AMINOIMIDAZOLE DERIVATIVES | K.U. Leuven Research and Development (BE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002068395-A1 | HIV INHIBITING N-AMINOIMIDAZOLE DERIVATIVES | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2002-09-06 | — | — | WO | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140186306-A1 | NOVEL AMPK AGONIST COMPOSITIONS AND METHODS OF USE | ADIPOR1, PRKAR2A, COL2A1 | UMPS 1599/4885KDM4E 1797/4885MAPT 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.